Shares of ZIOPHARM Oncology Inc (ZIOP) Drops by -17.05%

ZIOPHARM Oncology Inc (ZIOP) : During the past 4 weeks, traders have been relatively bearish on ZIOPHARM Oncology Inc (ZIOP), hence the stock is down -17.24% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -18.28% relative to the S&P 500. The 4-week change in the price of the stock is -13.62% and the stock has fallen -17.05% in the past 1 week. The stock has recorded a 20-day Moving Average of 14.16% and the 50-Day Moving Average is 23.88%.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP): The stock opened at $4.87 on Friday but the bulls could not build on the opening and the stock topped out at $5.23 for the day. The stock traded down to $4.69 during the day, due to lack of any buying support eventually closed down at $5.01 with a loss of -11.64% for the day. The stock had closed at $5.67 on the previous day. The total traded volume was 12,691,236 shares.


The company Insiders own 11.5% of ZIOPHARM Oncology Inc shares according to the proxy statements. Institutional Investors own 42.44% of ZIOPHARM Oncology Inc shares. In a related news,The officer (COO, CLO, and Secretary) of Ziopharm Oncology Inc, Belbel Caesar J sold 153,333 shares at $12.84 on November 19, 2015. The Insider selling transaction had a total value worth of $1,968,796. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.